目的 分析河南中醫(yī)藥大學第一附屬醫(yī)院2017—2019年抗腫瘤中藥制劑的應用情況及變化趨勢，為臨床合理用藥提供參考。方法 回顧性分析2017—2019年本院抗腫瘤中藥制劑的數(shù)據(jù)，如銷售金額、用藥頻度（DDDs）、日均費用（DDC）及排序比（B/A）等相關指標。結果 由于醫(yī)院加大對輔助用藥的監(jiān)管，本院2017—2019年抗腫瘤中藥制劑的銷售金額呈逐年下降趨勢。排序前10位的抗腫瘤中藥制劑以注射劑為主；其中3年來康艾注射液、康萊特注射液的銷售金額和DDDs均穩(wěn)居前列。華蟾素膠囊的銷售金額、DDDs和B/A逐年上升，DDC逐年下降，可見被接受程度較高。消癌平注射液、康艾注射液和康萊特注射液穩(wěn)居DDC排名前3位；近3年抗腫瘤中藥制劑的B/A的前10名中，抗腫瘤口服制劑占70%。結論 本院抗腫瘤中藥制劑以注射劑為主，且種類相對穩(wěn)定；個別藥物仍存在不合理使用的現(xiàn)象；應加強用藥管理，促進合理使用。

Objective To analyze the utilization and trend of antitumor Chinese medicine preparation in the First Affiliated Hospital of Henan University of Traditional Chinese Medicine from 2017 to 2019, to provide reference for clinical rational use. Methods By a retrospective review, the utilization of antitumor Chinese medicine preparation in the First Affiliated Hospital of Henan University of Traditional Chinese Medicine from 2017 to 2019 was selected, and consumption sum, defined daily doses (DDDs), daily drug cost (DDC), and rank ratio (B/A) were analyzed statistically. Results As the hospital strengthens the supervision of auxiliary drugs, the consumption sum of antitumor Chinese medicine preparation in 2017-2019 shows a downward trend year by year. The top 10 antitumor Chinese medicine preparation were mainly injections. In recent three years, the consumption sum and DDDs of Kangai Injections and Kanglaite Injections had been in the forefront. The consumption sum, DDDs and B/A of Cinobufacin Capsules increased year by year, while DDC decreased every year, which showed that it was highly accepted. Xiaoaiping Injections, Kangai Injections and Kanglaite Injections ranked top three in DDC. 70% of the top ten B/A antitumor Chinese medicine preparation were oral preparations over the 3 years. Conclusion In the First Affiliated Hospital of Henan University of Traditional Chinese Medicine, injection was the main antitumor Chinese medicine preparation, and the type was relatively stable. Some drugs still exist unreasonable use. The strengthening supervision is necessary to promote the rational drug use.

R979.1

國家自然科學基金青年科學基金資助項目（81603431）